KRAS and non-small cell lung carcinoma: CodeBreaK100: In KRAS G12C NSCLC, sotorasib demonstrated a 37% ORR; this combination with anti-PD-1 is being studied (NCT04185883); preliminary findings indicate improved response but higher liver toxicity.